Literature DB >> 28448298

Anesthetic consideration for neuromuscular diseases.

Jeffery A Katz1, Glenn S Murphy.   

Abstract

PURPOSE OF REVIEW: The aim of this review is to examine data relating to perioperative management of the patient with neuromuscular disorders RECENT
FINDINGS: Patients with pre-existing neuromuscular disorders are at risk for a number of postoperative complications that are related to anesthetic drugs that are administered intraoperatively. Careful preoperative assessment is necessary to reduce morbidity and mortality. In particular, the risk of postoperative respiratory failure and need for long-term ventilation should be reviewed with patients. The use of succinylcholine should be avoided in muscular dystrophies, motor neuron diseases, and intrinsic muscle disease due to a risk of malignant hyperthermia, hyperkalemia, rhabdomyolysis, and cardiac arrest. The use of quantitative neuromuscular monitoring should be strongly considered whenever nondepolarizing neuromuscular blocking agents are administered. A number of case series and reports have been recently published demonstrating that sugammadex can be safely used in patients with neuromuscular disease; the risk of residual neuromuscular is nearly eliminated when this agent is administered intraoperatively.
SUMMARY: Careful assessment and management of patients with underlying neuromuscular diseases is required to reduce postoperative complications. This article reviews the anesthetic implications of patients undergoing surgery with neuromuscular disorder.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28448298     DOI: 10.1097/ACO.0000000000000466

Source DB:  PubMed          Journal:  Curr Opin Anaesthesiol        ISSN: 0952-7907            Impact factor:   2.706


  9 in total

Review 1.  Care for Patients With Neuromuscular Disorders in the COVID-19 Pandemic Era.

Authors:  Yung-Hao Tseng; Tai-Heng Chen
Journal:  Front Neurol       Date:  2021-03-24       Impact factor: 4.003

2.  Anesthetic Considerations for an Adult Patient with Freeman-Sheldon Syndrome Undergoing Open Heart Surgery.

Authors:  S Viehmeyer; P Gabriel; K Bauer; S Bauer; R Sodian; J N Hilberath
Journal:  Case Rep Anesthesiol       Date:  2018-02-13

3.  Cognitive impairment in neuromuscular diseases: A systematic review.

Authors:  Marco Orsini; Ana Carolina; Andorinho de F Ferreira; Anna Carolina Damm de Assis; Thais Magalhães; Silmar Teixeira; Victor Hugo Bastos; Victor Marinho; Thomaz Oliveira; Rossano Fiorelli; Acary Bulle Oliveira; Marcos R G de Freitas
Journal:  Neurol Int       Date:  2018-07-04

4.  Opioid use may be associated with postoperative complications in myotonic dystrophy type 1 with high-grade muscular impairment.

Authors:  Chan-Sik Kim; Jin-Mo Park; Donghwi Park; Doo-Hwan Kim; Jin-Sung Park
Journal:  Sci Rep       Date:  2021-01-11       Impact factor: 4.379

Review 5.  The adult multidisciplinary respiratory neuromuscular clinic.

Authors:  Neeraj M Shah; Patrick B Murphy; Georgios Kaltsakas
Journal:  Breathe (Sheff)       Date:  2020-09

6.  Anesthesia of the Patient with Zhu-Tokita-Takenouchi-Kim (ZTTK) Syndrome: A Case Report.

Authors:  Jan Hudec; Martina Kosinova
Journal:  Children (Basel)       Date:  2022-06-11

7.  Perioperative management of immune-mediated necrotizing myositis.

Authors:  Mar Montané-Muntané; Júlia Vidal-Sánchez; Eva Rivas; Graciela Martínez-Pallí
Journal:  Braz J Anesthesiol       Date:  2022-03-14

Review 8.  Anaesthesia and neuromuscular disorders: what a neurologist needs to know.

Authors:  Heinz Jungbluth; Nicol C Voermans; Luuk R van den Bersselaar; Marc M J Snoeck; Madelief Gubbels; Sheila Riazi; Erik-Jan Kamsteeg
Journal:  Pract Neurol       Date:  2020-10-27

Review 9.  Mapping the current evidence on the anesthetic management of adult patients with neuromuscular disorders-a scoping review.

Authors:  Luuk R van den Bersselaar; Madelief Gubbels; Sheila Riazi; Luc Heytens; Heinz Jungbluth; Nicol C Voermans; Marc M J Snoeck
Journal:  Can J Anaesth       Date:  2022-03-23       Impact factor: 6.713

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.